Amendment to MBS Item 61564 for PSMA PET/CT Imaging

Following the 2026 Federal Budget, the Australian Government has approved an important amendment to MBS item 61564, which covers PSMA PET/CT imaging for the restaging of recurrent prostate adenocarcinoma. Effective 1 November 2026, the longstanding restriction of twice per lifetime will be replaced with annual access — a change that removes a significant barrier for patients and clinicians alike.

The previous lifetime cap failed to reflect the clinical reality of prostate cancer management. For men with biochemical recurrence or progressive disease, PSMA PET/CT is an ongoing necessity, not a one-time scan. Annual access will support better-informed decisions around salvage therapy, treatment escalation, and trial eligibility, while also reducing out-of-pocket costs for patients.

Read more about the decision on the PCFA website.